Designing a sustained-release solid oral formulation for overactive bladder treatment: a quality by design approach
Background: Mirabegron, a first-in-class β3-adrenergic agonist used for managing overactive bladder (OAB), is well-documented in the literature. However, its low oral permeability results in poor bioavailability, limiting patient compliance and tolerability. To address this, the present study focuse...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Creative Pharma Assent
2025-02-01
|
| Series: | Journal of Applied Pharmaceutical Research |
| Subjects: | |
| Online Access: | https://japtronline.com/index.php/joapr/article/view/820 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!